Physicians

A new approach to pain

Gelmetix’s DXM is not a drug. It is a biological solution that intervenes at the early phase of degenerative disc disease. It restores water content and helps cells to return to their normal function. It provides a minimally invasive alternative to surgery or pain management and improvement in quality of life.

Patients

Going to the source of pain

Gelmetix’s DXM tackles the source of chronic low-back pain by helping to restore the disc itself and relieve pain^1,2. Injected under local anaesthetic, directly into the disc, which means an ambulant procedure. DXM is an investigational product and not yet publicly available.

Investors

A platform for development

Gelmetix’s patented polymer technology provides a platform for tackling pain and restoring movement for chronic low-back pain, and in joints throughout the body. Our gels also offer the potential to act as a carrier, allowing the introduction of regenerative agents. This flexibility creates great potential for Gelmetix to offer an extendable technology platform.

¹Gelmetix data on file (preclinical)
²An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study. Berlemann U, Schwarzenbach O. Eur Spine J. 2009;18:1706–1712.